Ziduo Li - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ziduo Li

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Blood|May 11, 2021

Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cellsKenneth P Micklethwaite, Kavitha Gowrishankar, Brian S Gloss, et al.

Haematologica|January 21, 2018

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphomaZiduo Li, Xinsheng Ju, Kenneth Lee, et al.

Journal of Immunology (Baltimore, Md. : 1950)|November 13, 2016

The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell PopulationXinsheng Ju, Pablo A Silveira, Wei-Hsun Hsu, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Blood|May 11, 2021

Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cellsKenneth P Micklethwaite, Kavitha Gowrishankar, Brian S Gloss, et al.

Haematologica|January 21, 2018

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphomaZiduo Li, Xinsheng Ju, Kenneth Lee, et al.

Journal of Immunology (Baltimore, Md. : 1950)|November 13, 2016

The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell PopulationXinsheng Ju, Pablo A Silveira, Wei-Hsun Hsu, et al.

Pageof 2